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alternative courses of action in terms of both their costs and
consequences,” consists of various analytical methods to assist
decision makers in achieving allocation efﬁciency [1]. It has been
used in many industrialized countries as one of the essential
criteria for coverage decisions. Use of economic evaluation, in
particular cost-effectiveness analysis, to set priorities for cover-
age has gained little support in the United States because of the
American public’s fear of rationing [2,3]. This distaste for consid-
ering cost when evaluating comparative beneﬁts and harms of
health care technologies was heightened by the FY 2013 Labor,
Health and Human Services, and Education Appropriations Bill
drafted by a House Appropriations subcommittee on July 18, 2012,
to ban any economic research from the National Institutes of
Health funding [4,5]; fortunately, the Bill was not enacted. Avert-
ing economic evaluation is like ignoring the elephant in the room
considering that the skyrocketing health care cost is threatening
the ﬁscal health of the United States, with health care spending
accounting for approximately 18% of the nation’s gross domes-
tic product in 2011 and projected to reach 25% by 2037 [6].
Allocation efﬁciency and priority settings are especially impor-
tant for diseases with fast diffusions of expensive new tech-
nologies, most noticeably cancer. The number of cancer
incidence cases and survivors in the United States in 2013
was 1.6 million and 14 million, respectively [7], with the cost
of cancer care reaching $125 billion in 2010 [8]. Many have
expressed a serious concern that the high costs of oncology
products could jeopardize the quality of cancer care [9–12]. In
this Commentary, we discuss the potential of economic evalu-
ation to assist the cancer care community, on both the research
and practice sides, in meeting the recently released recommen-
dations from the Institute of Medicine (IOM) on delivering high-
quality cancer care [6].
The IOM released a report titled, “Delivering High-Quality
Cancer Care: Charting a New Course for a System in Crisis,” on
September 10, 2013. Although this report updates and revisits the
recommendations prescribed in the 1999 report, “Ensuring Quality
of Cancer Care,” the new report expresses a sense of urgency in
delivering high-quality oncology care that is affordable to all
cancer patients in the United States [13]. High-quality cancer careee front matter Copyright & 2014, International S
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that is patient-centered, accessible, coordinated, and evidence-
based [6]. The urgency is due to several factors that have emerged
in the past decade and have been magniﬁed over time, including
an aging population, which is leading to a rapid increase in cancer
incidence, the rising costs of cancer care, the growing complexity
in cancer treatment, and an increasing health care workforce
shortage. Conversely, recent events are providing unique oppor-
tunities to improve the delivery of high-quality cancer care, such
as advancements in information technology, patient empower-
ment, and the passage of the Affordable Care Act [14].
The recommendations in the 1999 IOM report on cancer care
quality and those in the 2013 IOM report are summarized in
Table 1. Three distinct features in the 2013 recommendations are
as follows: 1) the emphasis on patient-centeredness (Recommen-
dation 1 [R1], R2); 2) the importance of the ﬁnancial aspects of
cancer care (R1, R10); and 3) the opportunity associated with
establishing a learning health care system (R7, R8). Patient-
centeredness is accomplished by understanding patient prefer-
ences and communicating information and presenting evidence,
including the costs and disease burden of treatment options, in
ways that are meaningful to patients. Economic evaluation
provides costs, outcomes, and cost-effectiveness information
that are highly relevant to achieving R1 and R10; generates
patient-preferences data that are inherent within patient-
centered decision making; and all the above information contrib-
utes to a learning health care system that continuously collects
and updates clinical and economic information. Below we dis-
cuss the role of economic evaluation in meeting three important
aspects of the recommendations stated above: value discussions,
allocation efﬁciency and affordability, and patient centeredness.Value Discussions
When affordability of cancer care is a potential barrier, discus-
sions about the value of treatment options between patients and
their health care providers should increase. The ﬁrst recommen-
dation from the IOM Quality of Cancer Care Committee advocates
understanding the preferences of patients and their families andociety for Pharmacoeconomics and Outcomes Research (ISPOR).
elationships to disclose.
Table 1 – Comparisons of recommendations from the 1999 and 2013 IOM Quality of Cancer Care Report.
1999 Recommendations 2013 Recommendations
1. Ensure patients undergoing procedures that are technically
difﬁcult to perform and have been associated with higher
mortality in lower volume settings receive care at facilities with
extensive experience
1. Provide patients and their families with understandable
information about cancer prognosis, treatment beneﬁts and
harms, palliative care, psychosocial support, and estimates of
the total and out-of-pocket costs
2. Use systematically developed guidelines based on the best
available evidence for prevention, diagnosis, treatment, and
palliative care
2. Provide patients with end-of-life care consistent with their
needs, values, and preferences
3. Measure and monitor the quality of care using a core set of
quality measures
3. Ensure coordinated and comprehensive patient-centered care
4. Ensure the following elements of quality care for each individual
with cancer: experienced professionals who make
recommendations about initial cancer management, an agreed-
upon cancer plan that outlines goals of care, access to the full
complement of resources necessary to implement the care plan,
access to high-quality clinical trials, policies to ensure full
disclosure of information about appropriate treatment options, a
mechanism to coordinate services, and psychosocial support
services and compassionate care
4. Ensure that all individuals caring for cancer patients have
appropriate core competencies
5. Ensure quality of care at the end of life, particularly the
management of cancer-related pain and timely referral to
palliative and hospice care
5. Expand the breadth of data collected in cancer research for older
adults and patients with multiple comorbid conditions
6. Federal and private research sponsors should invest in clinical
trials to address questions about cancer care management
6. Expand the depth of data collected in cancer research through a
common set of data elements that capture patient-reported
outcomes, relevant patient characteristics, and health behaviors
7. A cancer data system that can provide quality benchmarks for
use by systems of care (e.g., hospitals, provider groups, and
managed care systems) is needed
7. Develop a learning health care information technology system
for cancer that enables real-time analysis of data from cancer
patients in various care settings
8. Research sponsors should support national studies of recently
diagnosed individuals with cancer, using information sources
with sufﬁcient detail to assess patterns of cancer care and factors
associated with the receipt of good care, and also training for
cancer care providers interested in health services research
8. Develop a national quality reporting program for cancer care as
part of a learning health care system
9. Services for the uninsured and underinsured should be enhanced
to ensure entry to, and equitable treatment within, the cancer
care system
9. Implement a national strategy to reduce disparities in access to
cancer care for underserved populations by leveraging
community interventions
10. Studies are needed to examine why speciﬁc segments of the
population (e.g., members of certain racial or ethnic groups, older
patients) do not receive appropriate cancer care
10. Improve the affordability of cancer care by leveraging existing
efforts to reform payment and eliminate waste
IOM, Institute of Medicine.
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information, including estimates of the total and out-of-
pocket costs. The IOM report deﬁned out-of-pocket costs as
expenses for medical care that are paid for by the patient and
can include deductibles, coinsurance, and co-payments for
covered services, and services that are not covered by insurance
[15]. Although oncologists are comfortable discussing clinical
information with their patients, many expressed discomfort in
incorporating costs into such discussions [16]—although a
national survey indicated that patients’ out-of-pocket spending
does inﬂuence treatment decisions [17]. Recognizing cost dis-
cussions as an important component of high-quality cancer
care, the American Society of Clinical Oncology established a
Cost of Care Task Force in 2007, which published a Guidance
Statement on the Cost of Cancer Care in 2009 to provide an
overview of the economic issues facing stakeholders in the
cancer community [18].
How can cancer-related economic evaluations generate
understandable information for patients and their clinicians
(R1)? To determine the full ﬁnancial impact of cancer treatment,
patients need to know their out-of-pocket expenses associatedwith a complete course of treatment. These should include
treatment possibly needed for complications, not just the differ-
ence in treatment costs between the therapeutic alternatives
because supportive care can be costly—a study estimated that
the average cost for hospitalizations to treat common complica-
tion of cancer treatments exceeded $7000 [19]. It is not realistic to
expect studies of economic evaluation to provide precise, patient-
speciﬁc estimates of out-of-pocket expenses for each treatment
option because the amount differs by patients’ treatment path-
way and insurance. Nevertheless, studies that present a detailed
cost table that itemizes every relevant cost element and the
associated unit cost will serve as a useful starting point. Using the
unit cost information as the national averages, clinicians can
aggregate over cost elements deemed to be relevant to the
patient’s treatment plan to arrive at an estimate of the total
costs and then apply the speciﬁc cost-sharing requirement in the
patient’s insurance to estimate the out-of-pocket costs. Although
estimates from the above approach may not be as accurate as
those obtained from ﬁnancial consultants or navigators at pro-
viders’ facilities, not all facilities have the resource to employ
ﬁnancial consultants—oftentimes a back-of-the-envelope
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 9 7 – 5 0 0 499calculation from the literature is the only resource that clinicians
and patients can access in a timely manner.
It should be noted that economic evaluation often emphasizes
the differences between the study comparators (e.g., incremental
costs and incremental effectiveness) to assist decision makers in
understanding the trade-offs between new and existing inter-
ventions. The focus on the “increments” sometimes prompts
researchers to neglect certain cost elements (e.g., costs of com-
plications or follow-ups) and justify such choice by claiming that
these elements are similar between interventions and thus
would be a “wash” under the calculation of increments. This
approach, although reduces the complexity of data collection and
is theoretically justiﬁable, compromises the usefulness of cost
information in the ﬁnancial discussions during patient-clinician
communications. In addition, many economic evaluations are
conducted from the perspective of a third-party payer and thus
do not collect information on out-of-pocket costs. To help
achieve R1 in the 2013 IOM report, future cancer-related eco-
nomic evaluation research should be mindful of the type of cost
information that may be helpful to the discussions of costs
between patients and clinicians and present study ﬁndings in a
format that is transparent, easily understandable, and adoptable.
Studies using the patient perspective will meet such
information need.Allocation Efﬁciency and Affordability
Economic evaluation provides decision makers with analytical
tools to improve allocation efﬁciency and assess the affordability
of health care; these analyses offer invaluable insights into
interventions or payment mechanisms designed to improve the
affordability of cancer care (R10). Although there is no commonly
accepted threshold of the incremental cost-effectiveness ratio
(ICER) in the United States, an excessively high ICER (e.g., over
$150,000 per quality-adjusted life-year [QALY] for studies using a
societal perspective) should prompt clinicians to initiate a con-
versation with their patients on the “value” of new therapy by
discussing the trade-off between costs and QALYs because a high
ICER is often an indication that the new therapy is much more
expensive than its therapeutic alternative(s) but may bring only a
small improvement in QALY. Another important analysis under
economic evaluation is budget impact analysis (BIA), which
incorporates the uptake and diffusion of technologies from a
system perspective and therefore provides information on the
affordability of a new technology [20]. Depending on the disease
prevalence and the standard of care in current practice, it is
possible that a new drug considered not to be cost-effective can
be affordable (e.g., orphan drugs) and vice versa. BIA is especially
helpful in evaluating the ﬁnancial impact of new payment
policies because changes in reimbursement can hinder or boost
the uptake and diffusion of new technologies. Collectively, CEA
and BIA generate critical information to achieve R10, with CEA
helping decision makers to identify possible waste in the system
and BIA guiding the direction of payment reforms to improve the
affordability of cancer care.Patient Centeredness
Patient centeredness reﬂects responsiveness to expressed needs
and desires of patients to obtain information relevant to their
values and the medical decisions that they make. Economic
evaluations in cancer can provide meaningful information on
the entire burden of cancer and associated care. This can be
accomplished by describing the patient cost sharing components
as well as broadening the scope of costs beyond the narrowdeﬁnition of direct medical costs by incorporating a broader
deﬁnition of cost that includes indirect and intangible costs. In
addition, economic evaluation research provides an opportunity
for patients to engage in research to better understand those
broader patient-centered cost considerations. Patient engage-
ment across the continuum of research would identify patient
burden and cost outcomes that inﬂuence patient treatment
choice and decision making [21]. In clinical practice, improved
communication surrounding the costs and patient burden would
facilitate a higher quality of cancer care. By banning funding for
economic research, the government will create large gaps in
evidence surrounding one of the most patient-centered aspects
of high-quality, affordable cancer care—the cost.American Exceptionism?
Is the cancer care crisis depicted in the recent IOM report a
phenomenon unique to the United States? The attempt to ban
economic research symbolized a shortsighted decision based on
an unfounded fear of rationing. If succeeded, it can severely limit
our ability to meet IOM recommendations and deliver high-
quality cancer care. Several jurisdictions, including Australia,
Canada, The Netherlands, and the United Kingdom, have used
economic evaluation in making drug coverage decisions. Mason
et al. [22] compared the decisions in the United States (by the
Centers for Medicare & Medicaid Services, the Veterans Admin-
istration, and a Blues plan) with those in the United Kingdom (by
the National Institute for Health and Social Care and Scottish
Medicines Consortium) for cancer drugs approved by the Food
and Drug Administration since 2004 [22]. Although they found
that there was more restricted coverage in the United Kingdom
than in the United States, this restriction was not universal and
allowed coverage for patients who would beneﬁt the most. In
addition, it is becoming common for pharmaceutical companies
to offer “patient access schemes” in the United Kingdom,
whereby discounts or subsidies are offered to secure a recom-
mendation for broader use of the drug. In commenting on the
article by Mason et al. [22], Malin [23] noted, “We have a choice:
do we use science to help us reach consensus on what we are
willing to pay for new therapies and innovation, or do we leave
individual patients to wrestle with the skyrocketing costs of
cancer care and treatment determined by their ability to pay?”
The IOM Quality of Cancer Care Committee calls for collective
efforts from all participants and stakeholders to address the
challenges that impede the delivery of high-quality care in the
US cancer care system—a system in crisis. To accomplish this
mission, let’s talk about the elephant in the room.Acknowledgments
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